Vimarsana
Biggest News Aggregation in the World

Page 22 - Arix Bioscience News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Arix Bioscience. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Arix Bioscience Today - Breaking & Trending Today

Arix Bioscience PLC: Unaudited NAV for October 2022 - Vimarsana News

Arix Bioscience PLC: Unaudited NAV for October 2022

DJ Unaudited NAV for October 2022 Arix Bioscience PLC (ARIX) Unaudited NAV for October 2022 09-Nov-2022 / 07:00 GMT/BST Dissemination of a Regulatory Announcement, transmitted by EQS Group. The issuer

Arix Bioscience PLC: Holding(s) in Company - Vimarsana News

Arix Bioscience PLC: Holding(s) in Company

DJ Holding(s) in Company Arix Bioscience PLC (ARIX) Holding(s) in Company 20-Oct-2022 / 16:30 GMT/BST Dissemination of a Regulatory Announcement, transmitted by EQS Group. The issuer is solely responsible

Investegate |Arix Bioscience PLC Announcements | Arix Bioscience PLC: Portfolio Company Imara Announces Merger Agreement with Enliven Therapeutics - Vimarsana News

Investegate |Arix Bioscience PLC Announcements | Arix Bioscience PLC: Portfolio Company Imara Announces Merger Agreement with Enliven Therapeutics

Investegate announcements from Arix Bioscience PLC, Portfolio Company Imara Announces Merger Agreement with Enliven Therapeutics

Portfolio Company Imara Announces Merger Agreement with Enliven Therapeutics - Vimarsana News

Portfolio Company Imara Announces Merger Agreement with Enliven Therapeutics

Arix Bioscience PLC (ARIX) Portfolio Company Imara Announces Merger Agreement with Enliven Therapeutics 14-Oct-2022 / 07:00 GMT/BST D...

Pharma Cos. Imara And Enliven Therapeutics Agree To Merger - Vimarsana News

Pharma Cos. Imara And Enliven Therapeutics Agree To Merger

Arix Bioscience PLC subsidiary Imara Inc. and Enliven Therapeutics Inc. said on Friday they have agreed to merge in an all-stock deal to create a pharmaceutical company valued at approximately $300 million, according to a London Stock Exchange announcement.

Source: law360.com